CEPROTIN
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- CEPROTIN
- Generic name
- PROTEIN C CONCENTRATE HUMAN
- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 926914a9-78b2-40ea-b37d-2a55c09bf275
- SPL ID
- 1555f3bd-95c4-4c6f-b936-690de32f8397
- Version
- 15
- Effective date
- 2025-12-04
- Source export date
- 2026-11-13
- Source partition
- 11
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/0ccebc9befe0ec22afe916211b2687f6eef8ed163963720f103786a7f2d2e3ae/drug-label-0011-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:32:50
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125234 | derived:openfda.application_number |
| application number | BLA125234 | openfda.application_number | |
| brand name | CEPROTIN | openfda.brand_name | |
| generic name | PROTEIN C CONCENTRATE HUMAN | openfda.generic_name | |
| manufacturer name | Takeda Pharmaceuticals America, Inc. | openfda.manufacturer_name | |
| ndc | package | 0944-4176-01 | openfda.package_ndc |
| ndc | package | 0944-4177-05 | openfda.package_ndc |
| ndc | package | 64764-516-10 | openfda.package_ndc |
| ndc | package | 64764-515-50 | openfda.package_ndc |
| ndc | package | 0944-4179-10 | openfda.package_ndc |
| ndc | package | 0944-4178-02 | openfda.package_ndc |
| ndc | product | 0944-4177 | openfda.product_ndc |
| ndc | product | 0944-4179 | openfda.product_ndc |
| ndc11 | package | 64764051610 | derived:openfda.package_ndc |
| ndc11 | package | 00944417802 | derived:openfda.package_ndc |
| ndc11 | package | 64764051550 | derived:openfda.package_ndc |
| ndc11 | package | 00944417910 | derived:openfda.package_ndc |
| ndc11 | package | 00944417601 | derived:openfda.package_ndc |
| ndc11 | package | 00944417705 | derived:openfda.package_ndc |
| rxcui | 728491 | openfda.rxcui | |
| rxcui | 723871 | openfda.rxcui | |
| spl id | 1555f3bd-95c4-4c6f-b936-690de32f8397 | id | |
| spl set id | 926914a9-78b2-40ea-b37d-2a55c09bf275 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Discontinue administration of CEPROTIN if symptoms of hypersensitivity/allergic reactions occur. ( 2.1 , 5.1 , 6 ) Because CEPROTIN is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease agent. ( 5.2 , 11 ) Simultaneous administration of CEPROTIN with tPA and/or anticoagulants may increase the risk of bleeding. ( 5.3 ) CEPROTIN contains heparin. If heparin-induced thrombocytopenia is suspected, check platelet counts immediately and discontinue administration. ( 5.4 ) CEPROTIN contains sodium >200 mg. Inform patients on a low sodium diet and/or patients with renal impairment. ( 5.5 ) 5.1 Hypersensitivity CEPROTIN may contain traces of mouse protein and/or heparin as a result of the manufacturing process. Allergic reactions to mouse protein and/or heparin cannot be ruled out. If symptoms of hypersensitivity/allergic reaction occur, discontinue the injection/infusion. In case of anaphylactic shock, the current medical standards for treatment are to be observed. 5.2 Transmissible Infectious Agents Because CEPROTIN is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease agent. All infections suspected by a physician to have been possibly transmitted by this product should be reported by the physician or other healthcare provider to Takeda Pharmaceuticals at 1-877-TAKEDA-7 (1-877-825-3327). Discuss the risks and benefits of this product with your patient. 5.3 Bleeding Episodes Several bleeding episodes have been observed in clinical studies. Concurrent anticoagulant medication may have been responsible for these bleeding episodes. However, it cannot be completely ruled out that the administration of CEPROTIN further contributed to these bleeding events. Simultaneous administration of CEPROTIN and tissue plasminogen activator (tPA) may further increase the risk of bleeding from tPA. 5.4 Heparin-induced Thrombocytopenia (HIT) CEPROTIN contains trace amounts of heparin which may lead to Heparin-induced Thrombocytopenia, which can be associated with a rapid decrease of the number of thrombocytes. Identifying HIT is complicated because these symptoms may already be present in acute phase patients with severe congenital protein C deficiency. Determine the platelet count immediately and consider discontinuation of CEPROTIN. 5.5 Low Sodium Diet/Renal Impairment Inform patients on a low sodium diet that the quantity of sodium in the maximum daily dose of CEPROTIN exceeds 200 mg. Monitor patients with renal impairment closely for sodium overload.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The common adverse reactions related to CEPROTIN treatment observed were the following hypersensitivity or allergic reactions: lightheadedness and itching and rash. Common adverse reactions observed in clinical trials were rash, itching, and lightheadedness. ( 5.1 , 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety profile of CEPROTIN was based on 121 patients from clinical studies and compassionate use in severe congenital Protein C deficiency. Duration of exposure ranged from 1 day to 8 years. One patient experienced hypersensitivity/allergic reactions (itching and rash) and lightheadedness which were determined by the investigator to be related to CEPROTIN. No inhibiting antibodies to CEPROTIN have been observed in clinical studies. However, the potential for developing antibodies cannot be ruled out. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of CEPROTIN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Psychiatric Disorders: Restlessness Skin and Subcutaneous Tissue Disorders: Hyperhydrosis General Disorders and Administration Site Conditions: Injection Site Reaction
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.